Prothena Corporation plc

Prothena Announces Addition of Seasoned Executive to Board of Directors

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson’s Disease

Prothena to Present at JMP Securities Life Science Conference 2015 on June 23

Prothena’s NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association

Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association

Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases

Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson’s Disease and Movement Disorders

Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting

Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results at 20th Congress of the European Hematology Association

Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO Annual Meeting

Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update

The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for Parkinson’s Disease

Prothena to Present at Upcoming Investor Healthcare Conferences

Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences

Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares

Prothena Announces Proposed Offering of Ordinary Shares

Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson’s Disease

Prothena Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Financial Guidance and R&D Update

Prothena to Report Fourth Quarter and Full Year 2014 Financial Results and Host Webcast and Conference Call on March 5

Prothena to Present at the 2015 RBC Capital Markets’ Healthcare Conference in New York on February 25

Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis

Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York

Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis

Prothena Reports Third Quarter 2014 Financial Results and R&D Progress

Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress

Dr. Dale Schenk to Discuss Parkinson’s Disease at 2014 Rejuvenation Biotechnology Conference

Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson’s Disease

Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares

Prothena Announces Proposed Offering of Ordinary Shares

Prothena to Present at the Jefferies 2014 Global Healthcare Conference in New York